AstraZeneca PLC logo

AstraZeneca PLC AZN

$ 71.33 -0.12%

Annual report 2023
added 11-02-2024

report update icon

Country

britainBritain

IPO year

-

Industry

Biotechnology

Stock Exchange

NASDAQ GLOBAL

CEO

Mr. Pascal Soriot M.B.A.

Employees in the company

70 600

Shares

-

Market Cap[1]

$ 96.9 B

EBITDA (LTM)

$ 3.67 B

P/E (LTM)

46.96

P/S (LTM)

7.88

EPS (LTM)

1.36

AstraZeneca is a global biopharmaceutical company specializing in the research, development, and commercialization of drugs for the treatment of diseases in various therapeutic areas. The company was founded in 1999 through the merger of Astra AB and Zeneca Group plc and is headquartered in Cambridge, UK.

AstraZeneca operates in over 100 countries and employs more than 70,000 people worldwide. The company is a leader in the research and development of drugs for the treatment of cancer, cardiovascular disease, respiratory diseases, diabetes, and other serious illnesses.

AstraZeneca's portfolio includes a wide range of drugs, including some of the world's best-selling drugs such as Crestor, Symbicort, and Nexium. The company invests heavily in research and development to develop innovative therapies that can improve patients' lives and health. Is also committed to promoting sustainable and responsible business practices. The company aims to be carbon neutral by 2025 and reduce its impact on the environment. It has also implemented programs to support communities and patients around the world.

In recent years, AstraZeneca has made several significant acquisitions, including MedImmune, Pearl Therapeutics, and Alexion Pharmaceuticals. These acquisitions have helped expand the company's portfolio and strengthen its position as a leading biopharmaceutical company.

In summary, AstraZeneca is a global biopharmaceutical company with a strong commitment to research and development, sustainability, and social responsibility. Its products and services have a significant impact on the healthcare industry and the lives of millions of people worldwide.

Other stocks of industry "Biotechnology"

Issuer Price % 24h Market Cap Exchange Country
Sorrento Therapeutics Sorrento Therapeutics
SRNE
$ 0.27 -29.58 % $ 126 M Nasdaq Global Select Market usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
$ 1.47 -5.16 % $ 5.39 M Nasdaq Capital Market usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
$ 4.93 1.02 % $ 90.8 M Nasdaq Global Select Market britainBritain
Coherus BioSciences Coherus BioSciences
CHRS
$ 0.68 -5.71 % $ 64 M Nasdaq Global Market usaUSA
Advaxis Advaxis
ADXS
$ 0.31 -9.65 % $ 45.9 M Nasdaq Capital Market usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
$ 3.93 -5.76 % $ 99.8 M Nasdaq Capital Market usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
$ 6.2 - $ 154 M Nasdaq Capital Market usaUSA
Zymeworks Zymeworks
ZYME
$ 6.42 - $ 404 M NYSE canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
$ 10.5 - $ 231 M Nasdaq Global Market usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
$ 9.5 - $ 1.7 B Nasdaq Global Select Market usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
$ 2.58 -4.8 % $ 255 M Nasdaq Global Select Market usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
$ 0.56 7.23 % $ 2.72 M Nasdaq Global Select Market usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
$ 0.5 - $ 7.46 M Nasdaq Global Market israelIsrael
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
$ 179.68 - $ 10.9 B Nasdaq Global Market,SPB usaUSA
Albireo Pharma Albireo Pharma
ALBO
$ 44.15 -0.23 % $ 916 M Nasdaq Capital Market usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
$ 0.32 - $ 23.9 M Nasdaq Global Select Market usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 3.14 1.95 % $ 13.1 M Nasdaq Global Select Market chinaChina
Kiromic BioPharma Kiromic BioPharma
KRBP
$ 3.15 6.61 % $ 3.08 M Nasdaq Global Select Market usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
$ 18.44 - $ 1.94 B Nasdaq Capital Market canadaCanada
Celyad Oncology SA Celyad Oncology SA
CYAD
$ 0.47 - $ 12.5 M Nasdaq Global Market belgiumBelgium

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.